AbbVie's Arthritis Medicine Humira

AbbVie's Arthritis Medicine Humira

JB Reed/Bloomberg

The cash-and-stock offer would allow AbbVie to diversify its portfolio beyond its top drug, the arthritis medicine Humira, which generated 57 percent of its 2013 sales, according to data compiled by Bloomberg.